Cheat sheet
Status: Not FDA-approved
Reviewed
BPC-157
One of the most discussed names in gut and recovery. Volume of conversation is not the same as volume of human trials.
The evidence rail
How to read this- Mechanistic: reached
- Cell research: reached
- Animal research: reached
- Human observational: reached, limited data
- Human clinical trial: not reached
- Established clinical use: not reached
- Evidence
- Limited human dataRung 4 of 6, limited data. People were observed, surveyed, or followed, or given the peptide in a small study with no comparison group. Useful for patterns, silent on cause.
- Status
- Not FDA-approvedNot approved for use as a drug. Often sold as a research chemical.
What has it been studied for?
- Gut lining and injury models, mostly in animals
- Recovery and inflammation conversations in humans, with much thinner clinical data
What we know
- The preclinical literature is large
- It has been named in compounding and committee news
What we don’t
- Robust, replicated human clinical outcomes for the uses people talk about online
Bottom line
Volume of conversation is not volume of evidence.
Education only. Not medical advice. Not a protocol.
Keep reading
Related sheets
-
InflammationKPV
A fragment of alpha-MSH studied for inflammation and skin. Small human data.
-
Gut
Larazotide
One of the few names in this space with multiple human trials, studied around celiac and tight junctions.
-
Nerve / PainARA-290
Studied in nerve pain and inflammation. Small placebo-controlled trials exist. Large ones do not.
New sheets, the day they publish.
One email a week. The study type named, every time.